Evidence map›Paper›PMID 26296857›Full record

Trial reportJournal of the American Heart Association2015

Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial).

S Marlene Grenon, Christopher D Owens, Emily V Nosova, Millie Hughes-Fulford, Hugh F Alley, Karen Chong, Sandra Perez, Priscilla K Yen, John Boscardin, Jason Hellmann and 2 more

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 6 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01310270 nacompletednot on this map

The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation

TypeinterventionalSponsorUniversity of California, San FranciscoRan2011 to 2018Enrolled180ConditionsPeripheral Arterial DiseaseArmsPro-Omega, Omega 3 Fatty Acid
NCT02719665 nacompletednot on this mapstarted 2016, after this paper: background citation

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled30ConditionsPeripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular OcclusionArmsSPM Emulsion, Dose-modality, SPM Softgel, Dose-Modality, Placebo Softgel
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Omega-3 fatty acids for intermittent claudication.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

S Marlene GrenonDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.) Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA (M.G., C.D.O., M.H.F., S.P.) Vascular Integrated Physiology and Experimental Therapeutics (VIPERx) Lab, San Francisco, CA (M.G., C.D.O., H.F.A., K.C., S.P.).
Christopher D OwensDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.) Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA (M.G., C.D.O., M.H.F., S.P.) Vascular Integrated Physiology and Experimental Therapeutics (VIPERx) Lab, San Francisco, CA (M.G., C.D.O., H.F.A., K.C., S.P.).
Emily V NosovaDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.).
Millie Hughes-FulfordDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.) Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA (M.G., C.D.O., M.H.F., S.P.).
Hugh F AlleyDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.) Vascular Integrated Physiology and Experimental Therapeutics (VIPERx) Lab, San Francisco, CA (M.G., C.D.O., H.F.A., K.C., S.P.).
Karen ChongDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.) Vascular Integrated Physiology and Experimental Therapeutics (VIPERx) Lab, San Francisco, CA (M.G., C.D.O., H.F.A., K.C., S.P.).
Sandra PerezDepartment of Surgery, Veterans Affairs Medical Center, San Francisco, CA (M.G., C.D.O., M.H.F., S.P.) Vascular Integrated Physiology and Experimental Therapeutics (VIPERx) Lab, San Francisco, CA (M.G., C.D.O., H.F.A., K.C., S.P.).
Priscilla K YenDepartment of Biostatistics, University of California Los Angeles, Los Angeles, CA (P.K.Y.).
John BoscardinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA (J.B.).
Jason HellmannCenter for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (J.H., M.S.).
Matthew SpiteCenter for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (J.H., M.S.).
Michael S ConteDepartment of Surgery, University of California, San Francisco, San Francisco, CA (M.G., C.D.O., E.V.N., M.H.F., H.F.A., K.C., M.S.C.).
University of California, San Francisco · USBrigham and Women's Hospital · USSan Francisco VA Medical Center · USUniversity of California, Los Angeles · US

Funding

CTSA: K12 COMPONENTKL2RR024130 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$19.3M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Role of Inflammation-Resolving Lipid Mediators In Ischemic RevascularizationR01HL106173 · NHLBI · UNIVERSITY OF LOUISVILLE · PI SPITE, MATTHEW R · 2011 to 2023
$5.7M
Suppression of the Immune Response in Spaceflight and AgingUH3AG037628 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI HUGHES-FULFORD, MILLIE · 2012 to 2014
$2.3M
Specialized lipid mediators and mechanisms of resolution in vascular injuryR01HL119508 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CONTE, MICHAEL S · 2013 to 2016
$1.5M
Effects of fish oil on inflammation and vascular function in claudicantsK23HL122446 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRENON, MARLENE · 2014 to 2017
$806k
Nutrient excess alters resolution of inflammation in diabetes and obesityF32HL116186 · NHLBI · UNIVERSITY OF LOUISVILLE · PI HELLMANN, JASON L · 2013 to 2015
$159k
NCATS NIH HHS KL2 TR000143NCRR NIH HHS KL2RR024130NHLBI NIH HHS 1K23HL122446-01NHLBI NIH HHS F32 HL116186NHLBI NIH HHS HL106173NHLBI NIH HHS HL116186NHLBI NIH HHS K23 HL122446NHLBI NIH HHS R01 HL106173NHLBI NIH HHS R01 HL119508NIA NIH HHS UH3 AG037628
6 · The paper itself

Abstract

backgroundPatients with peripheral artery disease (PAD) experience significant morbidity and mortality. The OMEGA-PAD I Trial, a randomized, double-blinded, placebo-controlled trial, addressed the hypothesis that short-duration, high-dose n-3 polyunsaturated fatty acids (n-3 PUFA) oral supplementation improves endothelial function and inflammation in PAD. METHODS AND

resultsEighty patients with stable claudication received 4.4 g of fish oil or placebo for 1 month. The primary end point was endothelial function as measured by brachial artery flow-mediated vasodilation. Secondary end points included biomarkers of inflammation, n-3 polyunsaturated fatty acids metabolome changes, lipid profile, and walking impairment questionnaires. Although there was a significant increase in FMD in the fish oil group following treatment (0.7±1.8% increase from baseline, P=0.04), this response was not different then the placebo group (0.6±2.5% increase from baseline, P=0.18; between-group P=0.86) leading to a negative finding for the primary endpoint. There was, however, a significant reduction in triglycerides (fish oil: -34±46 mg/dL, P<0.001; placebo -10±43 mg/dL, P=0.20; between-group differential P-value: 0.02), and an increase in the omega-3 index of 4±1% (P<0.001) in the fish oil group (placebo 0.1±0.9%, P=0.49; between-group P<0.0001). We observed a significant increase in the production of pathway markers of specialized pro-resolving mediators generated from n-3 polyunsaturated fatty acids in the fish oil group.

conclusionsHigh-dose, short-duration fish oil supplementation did not lead to a different response in the primary end point of endothelial function between the treatment and placebo group, but improved serum triglycerides and increased the production of downstream n-3 polyunsaturated fatty acids-derived products and mediators in patients with PAD. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov/. Unique identifier: NCT01310270.

Indexed as

Dietary SupplementsAdministration, OralAgedBiomarkersBrachial ArteryDouble-Blind MethodExercise ToleranceFatty Acids, Omega-3FemaleFish OilsHumansInflammation MediatorsMaleMiddle AgedPeripheral Arterial DiseaseSan FranciscoBiomarkersFatty Acids, Omega-3Fish OilsInflammation MediatorsTriglyceridesfish oiln‐3 polyunsaturated fatty acidsperipheral artery diseasespecialized pro‐resolving mediatorsvascular function

Identifiers

PMID26296857
PMCPMC4599461
OpenAlexW2152230223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.